The first-line therapy of patients with prolactinomas is treatment with dopamine agonists (DA), which can normalize PRL levels and reduce tumor volumes in ∼80% of patients.[5,6] Patients who are medically nonresponsive or intolerant to drug therapy are subsequently obliged to cease drug treatment. Here, PRL is linked to neoplasm.